RxSight Names Conway Chief Commercial Officer, Shields EVP of Sales

RxSight has appointed Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy, the company announced in a release distributed via citybiz.

The move puts two named executives atop the commercial organization at a medical device maker whose flagship product, the Light Adjustable Lens, depends on physician adoption and a disciplined selling motion across ophthalmic practices. The titles themselves signal the structure: Conway takes the top commercial seat, while Shields carries a combined sales-and-strategy mandate.

What does this change for the commercial team?

A Chief Commercial Officer appointment consolidates accountability for revenue-generating functions under one executive. For field sellers and regional managers at RxSight, that typically means a single owner for pricing decisions, territory design, and go-to-market sequencing — the day-to-day mechanics that determine quota setting and cycle-time expectations.

The EVP of Sales and Commercial Strategy role pairs the selling organization with planning. Companies that fuse these functions usually shorten the loop between what the field reports and how leadership reallocates coverage, a structural choice more than a cosmetic one.

What the announcement does and does not say

The release, as carried by citybiz, names the two appointees and their titles. It does not, based on the available text, specify start dates, reporting lines beyond the implied CCO-to-CEO link, prior roles the two executives held, or revenue targets attached to the new structure. Those gaps matter for anyone benchmarking the move against peer med-tech leadership changes; treat the appointments as confirmed facts and any strategic rationale as unverified until the company elaborates.

For a sales organization of RxSight's profile — a specialty device commercializing through surgeons rather than a broad enterprise motion — leadership changes of this kind tend to precede coverage-model revisions. Whether Conway and Shields restructure territories, adjust incentive compensation, or expand the sales team remains to be seen.

The company has not announced a date for its next detailed commercial update.